- Clinical Trials
Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise
Company achieves another milestone relating to its clinical trial strategy
Acclaim-2 Clinical Trial Combines REQORSA™ immunogene therapy with Merck & Co’s Keytruda®
Webinar series will feature a weekly company overview highlighting the Genprex’s gene therapy pipeline in cancer and diabetes
Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes
Collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).
As a disease involving mutated genes, cancer has always been a key target for emerging gene therapy technologies.
Company overview to highlight novel gene therapies for cancer and diabetes
What will it take to transition gene therapy from a treatment for diseases that only affect a few hundred thousand people worldwide to Type 1 diabetes, which is estimated to affect more than 45 million?
Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib